« Return to News | CROs/Service Providers

SynRG Becomes First Russian Member of European Forum for Good Clinical Practice

Wednesday, December 16, 2009 06:44 AM

Russia-based contract research organization (CRO) SynRG recently became the first Russian member of the European Forum for Good Clinical Practice (EFGCP), an organization created in 1993 to help develop and evaluate European health research. One of the EFGCP’s main purposes is to promote Good Clinical Practice (GCP) throughout Europe.

“We have a mutual interest in facilitating the conduct of clinical research projects in Russia to the highest standards of GCP, by providing appropriate information and training of investigators and ethics committees in these standards,” said Frank Wells, EFGCP’s Ethics Officer.

Through SynRG’s participation in the organization, EFGCP hopes to establish a dialogue with Russian non-profit and government institutions involved in clinical trials in Russia, as well as launch EFGCP training programs for Russia-based CRAs, investigators and members of the local ethics committees. SynRG hopes its participation in the organization will improve Russia’s clinical trial market and help the company attract foreign study sponsors.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.